|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
We found coordinate regulation of key metabolic enzymes with aerobic training in metabolic syndrome (aspartate aminotransferase 1, lactate dehydrogenase B, and pyruvate dehydrogenase-alpha(1)).
|
15347626 |
2005 |
|
Ochoa syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this study, we have constructed a genomic sequence map covering the entire UFS interval and narrowed the disease interval to a genomic region of 220 kb that harbor the newly identified ACDP1 gene in addition to part of the GOT1 gene which has already been excluded as a candidate for UFS.
|
12707951 |
2003 |
|
Ochoa syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
We also determined the precise location of the gene encoding for glutamate oxaloacetate transaminase (GOT1) within the new UFS critical region and determined its genomic structure.
|
10360399 |
1999 |
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A GOT1 inhibitor, (aminooxy)acetic acid, ameliorated asthma by shifting differentiation of T<sub>H</sub>17 cells to Treg cells.
|
31647966 |
2020 |
|
Kidney Failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dual-layer spectral detector CT using 50 keV VMI enabled reducing the CM dose by 50 % without CCAT image quality degradation in patients with renal insufficiency.
|
30407841 |
2019 |
|
Status Epilepticus
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the present study, rats were treated with vehicle or AST 1 h after SE onset and were injected once every other day for 2 weeks (total of seven times).
|
30983975 |
2019 |
|
Xeroderma Pigmentosum
|
0.010 |
Biomarker
|
disease |
BEFREE |
In fission yeast (<i>Schizosaccharomyces pombe</i>), genetic screens have previously uncovered a family of three xeroderma pigmentosum G (XPG)-related nucleases (XRNs), known as Ast1, Exo1, and Rad2.
|
30885940 |
2019 |
|
Enzyme inhibition disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In this work, we first examined the enzyme inhibition of over 500 compounds against GOT1 in vitro.
|
31605927 |
2019 |
|
Renal Insufficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dual-layer spectral detector CT using 50 keV VMI enabled reducing the CM dose by 50 % without CCAT image quality degradation in patients with renal insufficiency.
|
30407841 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis of enzymes that mediate the conversion of glutamate to AKG shows that TAZ/YAP induce glutamic-oxaloacetic transaminase (GOT1) and phosphoserine aminotransferase (PSAT1) expression and that TAZ/YAP activity positively correlates with transaminase expression in breast cancer patients.
|
29661856 |
2018 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Inhibition of GOT1 sensitized the cancer cells to glucose deprivation, which was partially counteracted by oxaloacetate and phosphoenol pyruvate, metabolic intermediates downstream of GOT1.
|
29751795 |
2018 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma.
|
30035324 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High levels of GOT1 were further linked to poor survival as analysed by the GEPIA web tool, in thyroid and breast carcinoma and in lung adenocarcinoma.
|
29751795 |
2018 |
|
Metastatic melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The relevance of GOT1 as a potential target in cancer therapy was supported by a lung adenocarcinoma RNA-seq data set as well as the GEO:GSE database of metastatic melanoma where GOT1 expression was increased.
|
29751795 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Inhibition of GOT1 sensitized the cancer cells to glucose deprivation, which was partially counteracted by oxaloacetate and phosphoenol pyruvate, metabolic intermediates downstream of GOT1.
|
29751795 |
2018 |
|
Malignant tumor of cervix
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results showed that compared with adjacent normal tissue, the expression of <i>CCAT-1</i> in cervical cancer tissue was significantly upregulated.
|
28978096 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A CRC subcutaneous tumor model was performed to determine the impact of GOT1 inhibition on 5-FU efficacy in vivo.
|
28314989 |
2017 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selective inhibition of GOT1 with (aminooxy)acetic acid ameliorated experimental autoimmune encephalomyelitis in a therapeutic mouse model by regulating the balance between T<sub>H</sub>17 and iT<sub>reg</sub> cells.
|
28783731 |
2017 |
|
Fetal Growth Retardation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
AST1, within the PEG3 domain, was the only gene consistently reduced in IUGR in both fetal and maternal samples.
|
28679164 |
2017 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ASPA (aspartoacylase) and GOT1 (glutamic-oxaloacetic transaminase 1) had lower expression in GBM (associated with poor outcomes).
|
28245795 |
2017 |
|
Icterus
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Fourteen cases (60.87%) presented jaundice and marked cytolysis at the time of diagnosis (aspartate aminotransferase [AST] 1,106.91 U/l and alanine aminotransferase [ALT] 1,407.04 U/l).
|
28376624 |
2017 |
|
Cervix carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results showed that compared with adjacent normal tissue, the expression of <i>CCAT-1</i> in cervical cancer tissue was significantly upregulated.
|
28978096 |
2017 |
|
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ASPA (aspartoacylase) and GOT1 (glutamic-oxaloacetic transaminase 1) had lower expression in GBM (associated with poor outcomes).
|
28245795 |
2017 |
|
cervical cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results showed that compared with adjacent normal tissue, the expression of <i>CCAT-1</i> in cervical cancer tissue was significantly upregulated.
|
28978096 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil.
|
28314989 |
2017 |